title: Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
authors.forename: Saranjit
authors.initials: S
authors.lastname: Singh
authors.forename: T T
authors.initials: TT
authors.lastname: Mariappan
authors.forename: Hemant
authors.initials: H
authors.lastname: Bhutani
mesh_terms: D000904:Antibiotics, Antitubercular / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D001682:Biological Availability; D004338:Drug Combinations; D006801:Humans; D012293:Rifampin / Q000008:administration & dosage* / Q000493:pharmacokinetics*
chemical_list: D000904:Antibiotics, Antitubercular; D004338:Drug Combinations; D012293:Rifampin